• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    K

    Kushiro Rosai Hospital

    EST. 1960
    517论文总数
    5,164引用总数

    论文量&引用量时间轴

    机构学者

    论文(518)

    年份
    起
    –
    止
    排序
    1A Phase II Trial of Ramucirumab and Docetaxel As Second-Line Treatment for Patients with Advanced Gastric Cancer (HGCSG 1903)
    Yasuyuki Kawamoto,Kentaro Sawada,Kazuaki Harada,Iori Motoo,Takayuki Ando,Susumu Sogabe,Yoshimitsu Kobayashi,Masayoshi Dazai,Michio Nakamura,Kazuteru Hatanaka,Atsushi Ishiguro,Atsushi Sato,

    Ramucirumab has shown efficacy in combination with paclitaxel in the second-line treatment of advanced gastric cancer (AGC). The efficacy and safety regarding the combination therapy of ramucirumab and docetaxel have not been reported. This treatment could reduce the incidence of neuropathy and patients’ hospital visits. This was a multicenter, single-arm phase II trial. Patients with AGC who were refractory or intolerant to primary treatment were eligible. Patients received ramucirumab at a dose of 8 mg/kg on day1 and 15, and docetaxel at a dose of 60 mg/m2 on day1 of a 28-day cycle. The primary endpoint was overall response rate (ORR). The secondary endpoints were progression-free survival (PFS), overall survival (OS), relative dose intensity, and safety. A final analysis of efficacy and safety was performed in 35 patients. ORR was 25.7

    2026Gastric Cancer(2026)引用:17
    引用
    AI阅读
    加入学术空间
    2Adverse Karyotype Amplifies Risk in Secondary Acute Myeloid Leukemia (AML) and AML with Myelodysplasia-Related Changes
    Toshihiro Matsukawa,Shota Yoshida,Masahiro Onozawa, Fumiaki Fujii, Jun Nagai, Tomoki Takahashi,Shuichi Ota,Junichi Hashiguchi,Akio Mori,Takuto Miyagishima,Makoto Ibata,Yasutaka Kakinoki,

    BACKGROUND:Secondary acute myeloid leukemia (sAML) and AML with myelodysplasia-related changes (AML-MRC) are associated with poor prognosis, but the impact relative to de novo AML remains controversial. We investigated clinical and genetic features in a multicenter Japanese cohort before CPX-351 approval. METHODS:We retrospectively analyzed 294 patients with newly diagnosed AML registered in the Hokkaido Leukemia Net between 2022 and 2023. Propensity score matching was used to adjust baseline variables. Genetic profiles were assessed in 160 matched patients. RESULTS:In the matched cohort, sAML/AML-MRC did not show inferior overall survival compared with non-sAML/non-AML-MRC (P = 0.90). Adverse karyotypes were the predominant determinant among sAML/AML-MRC. Among sAML/AML-MRC patients, adverse karyotypes were associated with poorer survival than those without adverse karyotypes (P = 0.0075). In contrast, non-sAML/non-AML-MRC groups did not affect survival regardless of adverse karyotypes (P = 0.51). Among 65 patients with ELN 2017 adverse-risk, those with TP53 mutations had markedly shorter survival than those with TP53 wild-type (P = 0.018). CONCLUSIONS:sAML/AML-MRC with an adverse karyotype had a dismal outcome. These findings provide a benchmark for risk stratification in the pre- CPX-351 era.

    2026Hematology (Amsterdam, Netherlands)(2026)引用:2
    引用
    AI阅读
    加入学术空间
    3Predictors of the Early Discontinuation of Anamorelin Hydrochloride in Gastrointestinal Cancer-Related Cachexia: a Multicenter Retrospective Cohort Study (HGCSG2201).
    Kazuaki Harada,Shinya Kajiura,Kentaro Sawada,Kazuteru Hatanaka,Atsushi Sato,Ken Ito, Hotaka Tamura,Ayako Doi,Takayuki Ando,Michio Nakamura,Hiroshi Nakatsumi,Tetsuhito Muranaka,

    Anamorelin hydrochloride (ANAM), used to treat cancer cachexia, is often discontinued early in clinical practice. Herein, we explored the clinical factors associated with the early discontinuation (Ed) of ANAM and examined its effect on treatment outcomes. Clinical data of patients with gastrointestinal cancers who were administered ANAM between April and November 2021 from 16 institutions were retrospectively collected. Ed was defined as ANAM discontinuation within 4 weeks of initiation. ANAM efficacy was compared between the continuation (Co) and Ed groups. Of the 123 patients, 50 had an Ed of ANAM. The most common reasons were cancer progression (36

    2026Supportive Care in Cancer(2026)引用:1
    引用
    AI阅读
    加入学术空间
    4Genotype-Informed Drosophila Kinome Screening Prioritizes PRKX As a Candidate Vulnerability in Bladder Cancer
    TAKUYA MORIGUCHI, Chihiro Kamijo,Taku Kimura, Taiga Hirata,Reo Sato,Ryodai Yamamura,Takahiro Osawa,Nobuo Shinohara,Takashige Abe,Masahiro Sonoshita

    Muscle-invasive bladder cancer is molecularly heterogeneous, and the basal/squamous subtype frequently exhibits elevated EGFR expression and TP53 and RB1 alterations. Functional vulnerabilities associated with these alterations remain incompletely defined, while large-scale in vivo screening in mammalian models is experimentally demanding. Therefore, we developed a genotype-defined Drosophila melanogaster model combining Egfr overexpression, mutant p53, and Rbf suppression in Malpighian tubules. The resulting 3-hit model showed increased Malpighian tubule volume and reduced adult eclosion rate. A dominant modifier screen targeting 216 kinase genes identified 72 genes whose perturbation significantly increased the eclosion rate, and a complementary RNA interference screen identified eight kinases whose knockdown increased the eclosion rate. Among these hits, Pka-C3, which is a Drosophila ortholog of human PRKX, emerged as one of the strongest suppressors of the 3-hit phenotype. PRKX was prioritized for further study because public transcriptomic datasets showed higher PRKX expression in bladder tumors than in normal bladder tissue. PRKX knockdown reduced spheroid volume in four human bladder cancer cell lines with distinct EGFR, TP53, and RB1 profiles. Both small interfering RNAs produced significant reductions in two cell lines, whereas only one siRNA reached significance in the other two. These findings nominate PRKX as a candidate vulnerability in bladder cancer and highlight a cross-species approach that combines genotype-informed Drosophila screening with functional testing in human cancer cells to prioritize targets for further investigation. ### Competing Interest Statement Masahiro Sonoshita is a shareholder, co-founder, and Chief Scientific Officer of FlyWorks, K.K. and FlyWorks America Inc. The other authors declare no conflicts of interest. J-PEAKS, PJS00420230001 Japan Science and Technology Agency, https://ror.org/00097mb19, JPMJCR2333 Japan Society for the Promotion of Science Japan Science and Technology Agency, https://ror.org/00097mb19, JPMJSP2119 Nippon Shinyaku Research Grant Program Junior Scientist Promotion Project, Hokkaido University Photo-Excitonix Project, Hokkaido University Joint Research Program of the Institute for Genetic Medicine, Hokkaido University

    2026
    引用
    AI阅读
    加入学术空间
    5Development of a Catalog of Anticancer Drug Effects on the Human Gut Microbiome Across Cancer Types
    Kyoko Kurihara,Shunsuke A. Sakai,Naoko Iida,Kentaro Sawada,Satoshi Horasawa,Takao Fujisawa,Yoshiaki Nakamura, Shunichiro Kageyama,Katsuya Tsuchihara,Riu Yamashita
    2026CANCER SCIENCE(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 518 篇论文

    合作机构(100)

    Hokkaido University Hospital合作论文 159
    北海道大学合作论文 120
    Sapporo City General Hospital合作论文 104
    Teine Keijinkai Hospital合作论文 94
    斗南病院合作论文 68
    Misawa City Hospital合作论文 67
    社会医療法人北楡会合作论文 61
    Japanese Red Cross Narita Hospital合作论文 52
    Keiyukai Sapporo Hospital合作论文 46
    日本医科大学千葉北総病院合作论文 39

    机构统计